Scott Coleman
Corporate Officer/Principal at XILIO THERAPEUTICS, INC.
Profile
Scott Coleman is currently the Chief Development Officer at Xilio Therapeutics, Inc. He previously worked as the Vice President-Non-Clinical Development at Acceleron Pharma, Inc. Dr. Coleman holds a doctorate degree from North Carolina State University and an undergraduate degree from Northeastern University.
Scott Coleman active positions
| Companies | Position | Start |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2022 |
Former positions of Scott Coleman
| Companies | Position | End |
|---|---|---|
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Training of Scott Coleman
| North Carolina State University | Doctorate Degree |
| Northeastern University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Scott Coleman